Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia-Reference-Cited by-同舟云学术

Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia

Published:2016-05-03 Issue:1 Volume:16 Page:
ISSN:2052-1839
Container-title:BMC Hematology
language:en
Short-container-title:BMC Hematol

Author:

Garcia-Manero Guillermo,Almeida Antonio,Giagounidis Aristoteles,Platzbecker Uwe,Garcia Regina,Voso Maria Teresa,Larsen Stephen R.,Valcarcel David,Silverman Lewis R.,Skikne Barry,Santini Valeria

Publisher

Springer Science and Business Media LLC

Subject

Hematology,Molecular Biology

Link

http://link.springer.com/content/pdf/10.1186/s12878-016-0049-5.pdf

Reference43 articles.

1. Cazzola M, Malcovati L. Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Engl J Med. 2005;352:536–8.

2. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999;340:1649–60.

3. Hofmann WK, Lubbert M, Hoelzer D, Phillip Koeffler H. Myelodysplastic syndromes. Hematol J. 2004;5:1–8.

4. Ma X. Epidemiology of myelodysplastic syndromes. Am J Med. 2012;125 Suppl 7:2–5.

5. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadie M, Simonetti A, Lutz JM, Berrino F, HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms;Experimental Hematology;2024-02

2. Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling;International Journal of Molecular Sciences;2023-04-06

3. The role of HBG2, BCL11A, and HBS1L-MYB in early diagnosis of transfusion-dependent thalassemia among Egyptian children;The Egyptian Journal of Haematology;2023

4. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine;Leukemia & Lymphoma;2022-11-12

5. Updates on the Management of Acute Myeloid Leukemia;Cancers;2022-09-29